Onconetix, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1292767,
    "name": "Onconetix, Inc.",
    "stock_name": "Onconetix, Inc.",
    "full_name": "Onconetix, Inc.",
    "name_url": "stocks-analysis/onconetix-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.58",
    "chg": -0.38,
    "chgp": "-12.71%",
    "dir": -1,
    "prev_price": "2.95",
    "mcapval": "4.14",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US09610B1089",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "50.85 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/onconetix-inc-1292767-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Onconetix, Inc. Hits New 52-Week Low at $2.45 Amid Major Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/onconetix-inc-hits-new-52-week-low-at-245-amid-major-decline-3559439",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/OnconetixInc_priceRelatedfactors_3559439.png",
        "date": "2025-09-23 15:55:54",
        "description": "Onconetix, Inc., a microcap pharmaceutical company, recently hit a 52-week low, reflecting a significant decline in performance over the past year. With a market capitalization of around USD 4 million, the company faces challenges, including a low price-to-book ratio and a concerning debt-to-equity ratio, raising questions about its financial stability."
      },
      {
        "title": "Is Onconetix, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-onconetix-inc-technically-bullish-or-bearish-3548941",
        "imagepath": "",
        "date": "2025-09-20 20:28:56",
        "description": "As of 12 September 2025, the technical trend for Onconetix, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Bollinger Bands also showing a bearish signal. While the MACD remains mildly bullish on both weekly and monthly time frames, the overall trend is tempered by the bearish signals from the moving averages and Bollinger Bands. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -94.4% versus the S&P's 12.22%...."
      },
      {
        "title": "Is Onconetix, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-onconetix-inc-overvalued-or-undervalued-3544521",
        "imagepath": "",
        "date": "2025-09-20 18:48:34",
        "description": "As of 29 August 2024, the valuation grade for Onconetix, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative P/E ratio of -0.4976 and an EV to EBITDA ratio of -1.7044, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. Additionally, the lack of a PEG ratio indicates that growth expectations may not justify the current valuation.\n\nIn comparison to peers, Onconetix, Inc. is underperforming, especially when contrasted with the broader industry metrics. For instance, while Onconetix has a negative P/E, other companies in the pharmaceuticals and biotechnology sector typically exhibit positive valuations. The recent stock performance further underscores this valuation concern, as Onconetix has seen a staggering YTD return of -94.4% compared to a 12...."
      }
    ],
    "total": 5,
    "sid": "1292767",
    "stock_news_url": "https://www.marketsmojo.com/news/onconetix-inc-1292767"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Onconetix, Inc. Hits New 52-Week Low at $2.45 Amid Major Decline

2025-09-23 15:55:54

Onconetix, Inc., a microcap pharmaceutical company, recently hit a 52-week low, reflecting a significant decline in performance over the past year. With a market capitalization of around USD 4 million, the company faces challenges, including a low price-to-book ratio and a concerning debt-to-equity ratio, raising questions about its financial stability.

Is Onconetix, Inc. technically bullish or bearish?

2025-09-20 20:28:56

As of 12 September 2025, the technical trend for Onconetix, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Bollinger Bands also showing a bearish signal. While the MACD remains mildly bullish on both weekly and monthly time frames, the overall trend is tempered by the bearish signals from the moving averages and Bollinger Bands. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -94.4% versus the S&P's 12.22%....

Is Onconetix, Inc. overvalued or undervalued?

2025-09-20 18:48:34

As of 29 August 2024, the valuation grade for Onconetix, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative P/E ratio of -0.4976 and an EV to EBITDA ratio of -1.7044, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. Additionally, the lack of a PEG ratio indicates that growth expectations may not justify the current valuation. In comparison to peers, Onconetix, Inc. is underperforming, especially when contrasted with the broader industry metrics. For instance, while Onconetix has a negative P/E, other companies in the pharmaceuticals and biotechnology sector typically exhibit positive valuations. The recent stock performance further underscores this valuation concern, as Onconetix has seen a staggering YTD return of -94.4% compared to a 12....

View All News